ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2026
[Impact of coexistent low-grade components on the prognosis of high-grade non-muscle invasive bladder cancer].
Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the impact of coexisted low-grade components on the prognosis of patients with high-grade solitary primary non-muscle invasive bladder cancer (NMIBC).
methodsA retrospective analysis was conducted on patients diagnosed with primary, solitary, high-grade non-muscle invasive bladder cancer (NMIBC) who underwent transurethral resection of bladder tumor (TURBT) at Peking University People' s Hospital between January 2015 and December 2019. All patients received single-dose intravesical chemotherapy within 24 hours after TURBT. Only patients accetpting adequate adjuvant intravesical chemotherapy were included for further analysis. Adequate intravesical chemotherapy was defined as weekly instillation for 8 weeks and monthly instillation for at least 6 months. All patients were strictly followed up according to the preestablished schedule with cystoscopic surveillance. The primary endpoint was recurrence free survival. Kaplan-Meier curve was used to compare the recurrence free survival of mHG group and pHG group. Univariable and multivariable Cox regression was conducted to evaluate the risk factors for tumor recurrence. Patients with variant histology, concurrent upper tract urothelial carcinoma, and incomplete resection which required re-TURBT were excluded. Patients without single instillation postoperative were also eliminated from the final cohort.
resultsA total of 167 patients were enrolled in the final cohort, with 35 patients having mixed high-grade tumors (mHG) and 132 patients having pure high-grade tumors (pHG). The median follow-up time was 39.32 (26.82, 61.37) months. Baseline characteristics were well balanced between the two groups with regard to age, gender, pathological characteristics and instillation doses. Compared with the mHG group, the 5-year recurrence-free survival rate (RFS) of the pHG group was significantly lower (80.0%
conclusionCoexistence of low-grade component in pathological specimen was associated with lower recurrence rate in patients with primary, solitary high-grade non-muscle invasive bladder cancer. Thus, it should be considered as a favorable pathological feature in bladder cancer patients.
Indexed as
Identifiers
42493448PMC13402068What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.